379 related articles for article (PubMed ID: 19355966)
1. Antiviral role of toll-like receptor-3 agonists against seasonal and avian influenza viruses.
Wong JP; Christopher ME; Viswanathan S; Dai X; Salazar AM; Sun LQ; Wang M
Curr Pharm Des; 2009; 15(11):1269-74. PubMed ID: 19355966
[TBL] [Abstract][Full Text] [Related]
2. Activation of toll-like receptor signaling pathway for protection against influenza virus infection.
Wong JP; Christopher ME; Viswanathan S; Karpoff N; Dai X; Das D; Sun LQ; Wang M; Salazar AM
Vaccine; 2009 May; 27(25-26):3481-3. PubMed ID: 19200852
[TBL] [Abstract][Full Text] [Related]
3. Recent Patents on development of nucleic acid-based antiviral drugs against seasonal and pandemic influenza virus infections.
Saravolac EG; Wong JP
Recent Pat Antiinfect Drug Discov; 2007 Jun; 2(2):140-7. PubMed ID: 18221170
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
Kobayashi M; Kodama M; Noshi T; Yoshida R; Kanazu T; Nomura N; Soda K; Isoda N; Okamatsu M; Sakoda Y; Yamano Y; Sato A; Kida H
Antiviral Res; 2017 Mar; 139():41-48. PubMed ID: 28012921
[TBL] [Abstract][Full Text] [Related]
5. Broad-spectrum and virus-specific nucleic acid-based antivirals against influenza.
Wong JP; Christopher ME; Salazar AM; Sun LQ; Viswanathan S; Wang M; Saravolac EG; Cairns MJ
Front Biosci (Schol Ed); 2010 Jan; 2(2):791-800. PubMed ID: 20036985
[TBL] [Abstract][Full Text] [Related]
6. Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat Sigmodon hispidus model.
Boukhvalova MS; Sotomayor TB; Point RC; Pletneva LM; Prince GA; Blanco JC
J Interferon Cytokine Res; 2010 Apr; 30(4):229-42. PubMed ID: 20038196
[TBL] [Abstract][Full Text] [Related]
7. Nucleic acid-based antiviral drugs against seasonal and avian influenza viruses.
Wong JP; Christopher ME; Salazar AM; Dale RM; Sun LQ; Wang M
Vaccine; 2007 Apr; 25(16):3175-8. PubMed ID: 17280757
[TBL] [Abstract][Full Text] [Related]
8. [The substances active against influenza virus. Possibilities and prospects of application].
Kwiatek M; Kocik J; Bartoszcze M
Przegl Epidemiol; 2009; 63(4):487-94. PubMed ID: 20120945
[TBL] [Abstract][Full Text] [Related]
9. Double-Stranded Ribonucleic Acid-Mediated Antiviral Response Against Low Pathogenic Avian Influenza Virus Infection.
Ahmed-Hassan H; Abdul-Cader MS; Ahmed Sabry M; Hamza E; Sharif S; Nagy E; Abdul-Careem MF
Viral Immunol; 2018; 31(6):433-446. PubMed ID: 29813000
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity of the proteasome inhibitor VL-01 against influenza A viruses.
Haasbach E; Pauli EK; Spranger R; Mitzner D; Schubert U; Kircheis R; Planz O
Antiviral Res; 2011 Sep; 91(3):304-13. PubMed ID: 21777621
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines.
Jang YH; Jung EJ; Byun YH; Lee KH; Lee EY; Lee YJ; Seong BL
Vaccine; 2013 Jul; 31(33):3339-46. PubMed ID: 23742997
[TBL] [Abstract][Full Text] [Related]
12. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods.
Nguyen HT; Fry AM; Gubareva LV
Antivir Ther; 2012; 17(1 Pt B):159-73. PubMed ID: 22311680
[TBL] [Abstract][Full Text] [Related]
13. The NF-kappaB inhibitor SC75741 protects mice against highly pathogenic avian influenza A virus.
Haasbach E; Reiling SJ; Ehrhardt C; Droebner K; Rückle A; Hrincius ER; Leban J; Strobl S; Vitt D; Ludwig S; Planz O
Antiviral Res; 2013 Sep; 99(3):336-44. PubMed ID: 23811282
[TBL] [Abstract][Full Text] [Related]
14. Antiviral therapy of influenza.
McCullers JA
Expert Opin Investig Drugs; 2005 Mar; 14(3):305-12. PubMed ID: 15833061
[TBL] [Abstract][Full Text] [Related]
15. Virucidal activity of a scorpion venom peptide variant mucroporin-M1 against measles, SARS-CoV and influenza H5N1 viruses.
Li Q; Zhao Z; Zhou D; Chen Y; Hong W; Cao L; Yang J; Zhang Y; Shi W; Cao Z; Wu Y; Yan H; Li W
Peptides; 2011 Jul; 32(7):1518-25. PubMed ID: 21620914
[TBL] [Abstract][Full Text] [Related]
16. New drug-strategies to tackle viral-host interactions for the treatment of influenza virus infections.
van de Wakker SI; Fischer MJE; Oosting RS
Eur J Pharmacol; 2017 Aug; 809():178-190. PubMed ID: 28533172
[TBL] [Abstract][Full Text] [Related]
17. Influenza Virus: Small Molecule Therapeutics and Mechanisms of Antiviral Resistance.
Han J; Perez J; Schafer A; Cheng H; Peet N; Rong L; Manicassamy B
Curr Med Chem; 2018; 25(38):5115-5127. PubMed ID: 28933281
[TBL] [Abstract][Full Text] [Related]
18. Anti-influenza drugs: the development of sialidase inhibitors.
von Itzstein M; Thomson R
Handb Exp Pharmacol; 2009; (189):111-54. PubMed ID: 19048199
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in neuraminidase inhibitor development as anti-influenza drugs.
Feng E; Ye D; Li J; Zhang D; Wang J; Zhao F; Hilgenfeld R; Zheng M; Jiang H; Liu H
ChemMedChem; 2012 Sep; 7(9):1527-36. PubMed ID: 22807317
[TBL] [Abstract][Full Text] [Related]
20. Intranasal seasonal influenza vaccine and a TLR-3 agonist, rintatolimod, induced cross-reactive IgA antibody formation against avian H5N1 and H7N9 influenza HA in humans.
Overton ET; Goepfert PA; Cunningham P; Carter WA; Horvath J; Young D; Strayer DR
Vaccine; 2014 Sep; 32(42):5490-5. PubMed ID: 25128802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
